BioNJ, the advocate for the state’s life sciences sector, released a landmark white paper Tuesday titled “Life Sciences in New Jersey: Prescription for Sustained Leadership.” The report, informed by an in-depth analysis from McKinsey & Company, outlines an ambitious eight-year plan to ensure the Garden State remains a global leader in biopharma innovation while narrowing the gap between New Jersey and rival hubs like Boston and the San Francisco Bay Area.
The white paper highlights New Jersey’s current dominance, noting that the biopharmaceutical industry is a primary driver of the state’s prosperity.
Some of the topics highlighted include:
-
Economic impact: The sector generates $121 billion annually, accounting for 7.8% of New Jersey’s GDP.
-
Innovation leader: In 2024, New Jersey-based companies advanced more drug candidates than any other state in the nation.
-
Workforce excellence: Home to the nation’s largest and fastest-growing biopharma manufacturing workforce, the industry pays an average annual wage of over $182,100.
Despite being the nation’s second-largest biopharma hub, BioNJ CEO Debbie Hart noted there is “meaningful room to grow.”
The paper offers five key recommendations to the new Sherrill-Caldwell Administration to modernize the state’s ecosystem:
1. Elevate the State’s Global Profile
Develop a stronger “value proposition” to attract international investment. This includes recruiting specific industry segments like Contract Research Organizations (CROs) to accelerate clinical trials and treatment delivery.
2. Supercharge the Startup Ecosystem
Continue heavy investment in the NJEDA’s financial tools, such as the Angel Investor Tax Credit and the Net Operating Loss (NOL) program. The report also calls for increased funding for the Commission on Science, Innovation, and Technology (CSIT), which has historically delivered a 15x return on investment.
3. Foster Industry-Academia Collaboration
Expand the ResearchWithNJ platform to include all state academic institutions and create new federal R&D matching grants to turn campus breakthroughs into commercial successes.
4. Strengthen the Talent Pipeline
Attract and “reskill” premier talent through initiatives like NJ BioFutures, ensuring the workforce stays ahead of advancements in cell and gene therapy and AI-driven drug discovery.
5. Promote NJ as the Manufacturing Partner of Choice
Spur investment in Contract Development and Manufacturing Organizations (CDMOs) to ensure that when a drug is discovered in New Jersey, it is also made in New Jersey.
The timing of the report is strategic. Many of its recommendations have already been mirrored in the Governor’s “Driving New Jersey Forward” transition report, signaling a strong alignment between the private sector and the State House.
“The future of New Jersey’s life sciences sector depends on its ability to unite a strong legacy with forward-looking innovation,” Chris Cozic, BioNJ chair and EVP at Genmab said. “We look forward to working with the new Administration to ensure New Jersey remains the Medicine Chest of the World.”
The full white paper is now available for download here or on the BioNJ website, serving as a guiding document for policymakers through 2034.
